Business Wire

J.P. Morgan Launches Private Markets Data Solutions for Institutional Investors

22.10.2024 15:00:00 CEST | Business Wire | Press release

Share

Fusion by J.P. Morgan releases a new suite of private markets data services that delivers standardized data aggregated from multiple vendors and sources, allowing investors to analyze their complete portfolio across private and publicly traded holdings.

J.P. Morgan today announced the launch of its Private Markets Data Solutions for institutional investors, available through Fusion by J.P. Morgan. This is a comprehensive data management solution for private assets that enables investors, both General Partners (GP) and Limited Partners (LP), to analyze and gain transparency into their complete portfolio across public and private holdings and eliminate the manual processes of managing this operational workflow at scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241016890254/en/

null

Flowchart shows the capabilities of J.P. Morgan Fusion’s new suite of private markets data services. (Graphic: Business Wire)

The growth of alternative portfolios has presented investors with unique data challenges. The lack of a single, standardized source for private markets means investors are left with incomplete and fragmented data that is difficult to analyze. The process of manually extracting and integrating data from unstructured sources is time-consuming, costly, and error prone. Managing multiple vendors, data feeds, and portfolio administrators complicates data consolidation and transparency, affecting decision-making and necessitating specialized expertise and scalable technology, which further escalates costs and delays time to market.

Fusion minimizes the need for resource-intensive processes by offloading this workload to algorithms that work automatically, accelerating time to insights. Data is ingested from J.P. Morgan Securities Services and portfolio administrators, which is then complemented with reference data from vendors. Developed by J.P. Morgan’s data experts, Fusion’s proprietary AI-ML technology helps correct discrepancies and incompleteness and applies standard identifiers for consistency and easy interoperability. Clients receive standardized, enriched data that is consistent across diverse asset classes like private equity, real estate, venture capital, natural resources, and infrastructure, while preserving granular detail and linkage.

Tim Fitzgerald, Global Head of Securities Services, said, “Securities Services is committed to helping clients meet the challenges of an increasingly competitive private asset market with innovative data-driven solutions. Our platform empowers clients with more information to drive their decision making, while optimizing their workflow.”

To offer clients a single source for more complete, high-quality data that works across public and private assets, Fusion has incorporated data from Aumni, J.P. Morgan's private capital platform, and external leading data providers like Canoe Intelligence, MSCI Private Capital Solutions, and PitchBook. Investors can analyze and manage their data with the Fusion Data Explorer tool, allowing them to drill down into underlying assets and navigate across linked data points, for a deeper understanding of their holdings.

Gerard Francis, Head of Fusion, said, “Fusion is uniquely positioned to integrate private markets and client investment data, leveraging proprietary graph technology and AI-ML models for comprehensive portfolio transparency and interoperability. Our cloud-native platform supports data from multiple portfolio administrators and vendors, ensuring seamless integration, scalability, and a streamlined experience without legacy infrastructure constraints."

Fusion’s Data Mesh supports a variety of cloud-native channels, designed to simplify the process of integrating Fusion data into clients’ existing technology stack. For business users, the newly launched Fusion Drive enables desktop applications like Excel, Tableau, and Alteryx to connect directly to Fusion data, and receive updates automatically.

Learn more: fusion.jpmorgan.com/solutions/private-markets

Key Capabilities:

  • Private markets data integration: Fusion takes in reference data from leading providers like Aumni (J.P. Morgan’s private capital platform), Canoe Intelligence, MSCI Private Capital Solutions, and PitchBook.
  • Data ingestion from multiple fund and portfolio administrators: Fusion supports portfolio data from J.P. Morgan Securities Services and other portfolio administrators that clients use. Data is harmonized for seamless interoperability across administrators.
  • Data normalization: Data is normalized to look and feel the same, so it’s ready to be used across investors’ operating models. Fusion models data for clarity and consistency, applying standard identifiers and linking relevant datapoints.
  • Complete portfolio view and Data Explorer: Investors can view, analyze, and drill down into private market data using an intuitive exploration tool. The linked data model enables interoperability between private and public asset classes, portfolios and accounts, to easily dive deep and analyze.
  • Data management: Fusion gives clients powerful controls to apply rules-based adjustments and overrides to data. This functionality allows users to ensure data is fit-for-purpose across multiple lines of business without altering the underlying data or linkage.
  • Data Mesh: Fusion offers a suite of cloud-native channels for clients to integrate Fusion data directly into their tech stacks, including API, Jupyter Notebook, Snowflake, Databricks and more. Connect data directly to your desktop applications with Fusion Drive.

About Fusion by J.P. Morgan

Fusion is a cloud-native data technology solution that provides data management, analytics and reporting for institutional investors. Fusion builds on J.P. Morgan’s global operating model and rich data foundation as an industry-leading Securities Services provider to deliver benefits of scale and reduce costs. With a broad array of integrated solutions that span investment strategies, fund structures, asset types and geographies, J.P. Morgan Securities Services delivers the expertise, scale and capabilities to help our clients protect and grow their assets, optimize efficiency and maximize opportunities in diverse global markets.

About the Commercial & Investment Bank

J.P. Morgan’s Commercial & Investment Bank is a global leader in banking, payments, markets and securities services. Start-ups, companies, governments and institutions entrust us with their business in more than 100 countries worldwide. With $35.8 trillion of assets under custody and $966 billion in deposits, the Commercial & Investment Bank provides strategic advice, raises capital, manages risk, offers payment solutions, safeguards assets and extends liquidity in global markets. Further information about J.P. Morgan is available at www.jpmorgan.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241016890254/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye